Loading cancer entity…
Loading cancer entity…
Clinical trials
44 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | recruiting | Phase 2 | 314 | National Cancer Institute (NCI)NIH | 2 | Sep 24, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07808359 | Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma(APOLO) | not yet recruiting | Phase 2 | 58 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07815197 | Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer(PERSEUS) | not yet recruiting | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | active not recruiting | Phase 1 | 152 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02305654 | International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)(InPACT) | active not recruiting | Phase 3 | 200 | Institute of Cancer Research, United KingdomOTHER | 2 | Aug 31, 2026 | clinicaltrials |
| NCT07767266 | Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile Cancer | not yet recruiting | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04718584 | the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors | completed | Phase 2 | 27 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07110038 | DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma | recruiting | Phase 2 | 25 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06104618 | Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis | recruiting | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT06353906 | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer(PRIAM) | recruiting | Phase 2 | 27 | The Netherlands Cancer InstituteOTHER | 2 | Dec 8, 2025 | clinicaltrials |
| NCT05526989 | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | recruiting | Phase 2 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04996849 | Contemporary Characteristics of Penile Cancer | terminated | — | 499 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05999396 | FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer(CoRe_CC-3) | recruiting | Phase 1 | 89 | German Cancer Research CenterOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT02104063 | Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET](MRI-PET) | completed | — | 78 | Queen Mary University of LondonOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | terminated | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04224740 | Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer(HERCULES) | completed | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06068998 | Molecular Characterization of Penile Cancers in Developing Countries | completed | — | 24 | Latin American Cooperative Oncology GroupOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT03774901 | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma(PULSE) | unknown | Phase 2 | 32 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | terminated | Phase 2 | 6 | University of Alabama at BirminghamOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03943602 | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)(CaboPen) | unknown | Phase 2 | 37 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02541903 | Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma | terminated | Phase 2 | 8 | University of Alabama at BirminghamOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02279576 | Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)(PAZOPEN-SOGUG) | terminated | Phase 2 | 4 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | withdrawn | Phase 2 | 0 | Centre Leon BerardOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01526486 | Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer | completed | N/A | 29 | Emory UniversityOTHER | 1 | May 6, 2015 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials